Article
Radiology, Nuclear Medicine & Medical Imaging
Michael K. Farris, Niema B. Razavian, Ryan T. Hughes, James D. Ververs, Anna C. Snavely, Charles M. Leyrer, Karen E. Tye, Laura F. Allen, Heather Pacholke, Kathryn E. Weaver, Paul M. Bunch, Michael D. Chan, Hollins Clark, Gregory Puthoff, Joshua C. Farris, Cole R. Steber, Stacy Wentworth, Beverly J. Levine, Chandylen L. Nightingale, Janardhana Ponnatapura
Summary: Multidisciplinary collaboration between radiologists and radiation oncologists can optimize radiotherapy planning for locally advanced lung cancer and improve treatment outcomes.
ACADEMIC RADIOLOGY
(2023)
Article
Oncology
Chi-Lu Chiang, Chia- Shen, Hsu-Ching Huang, Han-Jhih Chang, Yu-Ting Huang, Chao-Hua Chiu
Summary: This study investigates the optimal approach for EGFR mutation testing in NSCLC patients using centrifuged effusion samples and proposes a cytology-based specimen triage. The proposed strategy improves the detection rate of EGFR mutations and provides an efficient testing strategy for patients with EGFR-mutant NSCLC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Pimpin Incharoen, Artit Jinawath, Lalida Arsa, Kaettipong Kamprerasart, Narumol Trachu, Nanamon Monnamo, Khantong Khiewngam, Dittapol Muntham, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana
Summary: This study explores the clinical correlates of ctDNA and tissue/plasma-based gene mutation status in different stages of NSCLC. The results show that ctDNA levels are variable and not significantly associated with clinical/surgical parameters in early-stage patients, but the clinical value of ctDNA testing is higher in advanced-stage and recurrent NSCLC. Therefore, using ctDNA testing in advanced-stage and recurrent NSCLC is feasible.
Review
Biochemistry & Molecular Biology
Hannah L. Tumbrink, Alena Heimsoeth, Martin L. Sos
Summary: EGFR mutations play a major role in druggable targets for lung adenocarcinoma, and optimization of EGFR inhibitors has significantly impacted treatment options. However, the emergence of resistance mutations during drug treatment has driven the need for rapid understanding of individual mutations for developing next-generation inhibitors. The field currently faces a large number of combinations of activating mutations and distinct resistance mutations, alongside the approval of osimertinib as a frontline drug for EGFR-mutant lung cancer.
Article
Oncology
Kirsty W. C. Lee, Molly S. C. Li, Wanxia Gai, Yat Ming Lau, Allen K. C. Chan, Oscar S. H. Chan, Chee Khoon Lee, Rebecca M. W. Yeung, Sherwood Y. H. Fung, Wai F. F. Cheung, Vivian W. W. Chan, Linda Leung, Kenny N. P. Kam, Tony S. K. Mok
Summary: This study aimed to validate the accuracy of detecting EGFR variants through PE-cfDNA using liquid biopsy in NSCLC patients. The results showed that PE-cfDNA was more sensitive than plasma in detecting EGFR sensitizing mutations. For the detection of T790M mutation, PE-cfDNA had lower sensitivity but could complement other testing methods. Therefore, PE-cfDNA can be used as one of the methods for detecting EGFR mutations in NSCLC patients.
Article
Medicine, General & Internal
Dipin Sudhakaran, Sheragaru Hanumanthappa Chandrashekhara, Sunil Kumar, Mohamed Sulaiman
Summary: Pleural lipomas are rare in the thoracic cavity, often solitary, small, and asymptomatic. Despite their benign nature, excision is recommended due to their potential for evolution.
Article
Oncology
Martin Filipits, Verena Kainz, Viktor Sebek, Herwig Zach, Liquid Biopsy Collaborative Study Grp
Summary: Liquid biopsy is a powerful tool to detect EGFR T790M mutation; there are various platforms with different sensitivities; if a negative result is obtained from a low sensitivity method, further testing or tissue biopsy should be performed to identify T790M positive patients for optimal second-line treatment with third-generation EGFR TKI.
Article
Multidisciplinary Sciences
Ha-Young Seo, Soon-Chan Kim, Woo-lee Roh, Young-Kyoung Shin, Soyeon Kim, Dong-Wan Kim, Tae Min Kim, Ja-Lok Ku
Summary: Malignant pleural effusion (MPE) is a crucial factor in the poor prognosis of non-small cell lung cancer (NSCLC). By analyzing genomic, transcriptomic, and pharmacologic data from MPE-derived NSCLC cell lines, this study found that these cell lines exhibit driver gene mutations and distinct translational subtypes. The drug responses of these cell lines also align with their genomic and transcriptomic characteristics.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Jeffrey Lombardi, Pauline Lory, Nils Martin, Didier Mayeur, Sandrine Combret, Aurelie Grandvuillemin, Charlene Boulay, Antonin Schmitt
Summary: The case report presented a breast cancer patient who developed pleural and pericardial effusions after T-DM1 treatment, but fully recovered after thoracentesis and discontinuation of the drug. No side effects were reported after switching to trastuzumab.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2021)
Article
Respiratory System
Jean Reinoso, Ghulam Aftab, Karthik Vijayan, Hiren J. Mehta
Summary: This study aimed to assess the utility of indwelling pleural catheter (IPC) in managing recurrent nonmalignant pleural effusion (NMPE) after lung cancer surgery. The results showed that all 12 patients achieved spontaneous pleurodesis with a low complication rate, indicating IPC as an effective treatment option for NMPE.
JOURNAL OF THORACIC DISEASE
(2023)
Article
Oncology
Balazs Gieszer, Zsolt Megyesfalvi, Viktoria Dulai, Judit Papay, Ilona Kovalszky, Jozsef Timar, Janos Fillinger, Tunde Harko, Orsolya Pipek, Vanda Teglasi, Eszter Regos, Gergo Papp, Zoltan Szallasi, Viktoria Laszlo, Ferenc Renyi-Vamos, Gabriella Galffy, Csaba Bodor, Balazs Dome, Judit Moldvay
Summary: This study suggests that high EGFR-aVAF in tumoral tissue predicts benefit from EGFR-TKI treatment in advanced LADC, and that exon 19 EGFR mutation is associated with high EGFR-aVAF and improved survival outcomes.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Medical Informatics
Shuo Wang, He Yu, Yuncui Gan, Zhangjie Wu, Encheng Li, Xiaohu Li, Jingxue Cao, Yongbei Zhu, Liusu Wang, Hui Deng, Mei Xie, Yuanyong Wang, Xidong Ma, Dan Liu, Bojiang Chen, Panwen Tian, Zhixin Qiu, Jinghong Xian, Jing Ren, Kun Wang, Wei Wei, Fei Xie, Zhenhui Li, Qi Wang, Xinying Xue, Zaiyi Liu, Jingyun Shi, Weimin Li, Jie Tian
Summary: This study introduced a fully automated artificial intelligence system (FAIS) that mined whole-lung information from CT images to predict EGFR genotype and prognosis with EGFR-TKI treatment. FAIS outperformed tumour-based deep learning models, providing a non-invasive method to detect EGFR genotype and identify high-risk EGFR mutation patients for TKI resistance.
LANCET DIGITAL HEALTH
(2022)
Review
Oncology
E. Heitzer, D. van den Broek, M. G. Denis, P. Hofman, M. Hubank, F. Mouliere, L. Paz-Ares, E. Schuuring, H. Sultmann, G. Vainer, E. Verstraaten, L. de Visser, D. Cortinovis
Summary: This paper reviews the challenges and current applications of ctDNA mutation testing in metastatic non-small cell lung cancer (NSCLC). The study finds that ctDNA mutation testing has potential value in complementing tissue biopsy, identifying resistance mechanisms, and assisting in therapy selection. It also provides insights into potential targets that may have been missed on tissue biopsy.
Article
Oncology
Markus Y. Wu, Eric W. Zhang, Matthew R. Strickland, Dexter P. Mendoza, Lev Lipkin, Jochen K. Lennerz, Justin F. Gainor, Rebecca S. Heist, Subba R. Digumarthy
Summary: KRAS G12C mutations in lung cancer are important oncogenic mutations that exhibit distinct primary tumor imaging features and patterns of metastasis compared to lung cancers driven by other genetic alterations. These unique imaging features may provide clues to the presence of KRAS G12C NSCLC and potentially guide management strategies in the future.
Article
Immunology
Jing Pan, Donghai Xiong, Qi Zhang, Katie Palen, Robert H. H. Shoemaker, Bryon Johnson, Shizuko Sei, Yian Wang, Ming You
Summary: In this study, immunogenic epitopes for common EGFR mutations in humans were identified and a multi-peptide vaccine (E-mut Vax) targeting these mutations was formulated. The E-mut Vax effectively prevented EGFR mutation-driven lung tumorigenesis in mouse models and enhanced Th1 responses in the tumor microenvironment while decreasing suppressive Tregs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Xiaofan Pu, Chaolei Zhang, Guoping Ding, Hongpeng Gu, Yang Lv, Tao Shen, Tianshu Pang, Liping Cao, Shengnan Jia
Summary: This study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyang
Summary: This study demonstrates the significance of PD-1 in EBV-infected lymphoma cells. Silencing PD-1 enhances the tumor targeting effect of EBV-specific killer T cells on B lymphocytes and attenuates the immune escape effect.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Qiliang Peng, Jialong Tao, Yingjie Xu, Yi Shen, Yong Wang, Yang Jiao, Yiheng Mao, Yaqun Zhu, Yulong Liu, Ye Tian
Summary: This study investigates the potential role of lipid metabolism-associated genes (LMAGs) in neoadjuvant chemoradiotherapy (nCRT) and immunotherapy for rectal cancer. The results suggest that the SREBF2 gene is a highly predictive factor for nCRT in rectal cancer and is associated with favorable prognosis. SREBF2 is also closely associated with immune cell infiltration and immunotherapy-related genes.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Shiquan Li, Nan Zhang, Yongping Yang, Tongjun Liu
Summary: This study investigated the potential molecular mechanism of SPDEF in immune evasion of colorectal cancer (CRC) and found that it suppresses immune evasion by activating CCL28 through the modulation of M2 polarization of macrophages. These findings provide a new research direction and potential therapeutic target for immunotherapy in CRC.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Manas Sehgal, Soundharya Ramu, Joel Markus Vaz, Yogheshwer Raja Ganapathy, Srinath Muralidharan, Sankalpa Venkatraghavan, Mohit Kumar Jolly
Summary: This study investigates the relationship between gene expression patterns and phenotypic plasticity and heterogeneity in colorectal cancer (CRC). The results demonstrate the interconnectedness between different Consensus Molecular Subtypes (CMS) of CRC and specific phenotypes such as epithelial and mesenchymal characteristics. Additionally, the study reveals correlations between metabolic pathways and phenotypic scores, as well as between PD-L1 activity and mesenchymal phenotype. Single-cell RNA sequencing analysis further confirms the heterogeneity of different CMS subtypes. These findings have important implications for understanding CRC heterogeneity and developing targeted therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yutong Zou, Siyao Guo, Yan Liao, Weidong Chen, Ziyun Chen, Junkai Chen, Lili Wen, Xianbiao Xie
Summary: This study found that ceramide metabolism is associated with the progression and clinical outcome of osteosarcoma by analyzing data from osteosarcoma patients. The gene ST3GAL1 plays an important role in osteosarcoma, regulating the tumor immune microenvironment and affecting T cell function. It may become a new target for the treatment of osteosarcoma.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Chuanhui Chen, Mengzhi Wan, Xiong Peng, Qing Zhang, Yu Liu
Summary: This study examines the function and mechanism of the ceRNA network centered around GPR37 in LUAD. The findings show that high expression of GPR37 in LUAD tissue samples is associated with poor prognosis, and it may regulate the expression of downstream target genes by competitively binding to lncRNA DLEU1 and miR-4458.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Junping Li, Hong Hu, Jinping He, Yuling Hu, Manting Liu, Bihui Cao, Dongni Chen, Xiaodie Ye, Jian Zhang, Zhiru Zhang, Wen Long, Hui Lian, Deji Chen, Likun Chen, Lili Yang, Zhenfeng Zhang
Summary: Sequential administration of CDC7 inhibitor XL413 after carboplatin enhances the chemotherapeutic effect of carboplatin on ovarian cancer cells, possibly by inhibiting homologous recombination repair activity and increasing the accumulation of chemotherapy-induced DNA damage.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Madison Catalanotto, Joel Markus Vaz, Camille Abshire, Reneau Youngblood, Min Chu, Herbert Levine, Mohit Kumar Jolly, Ana -Maria Dragoi
Summary: The study demonstrates that loss of FLASH in cancer cells leads to a hybrid E/M phenotype with high epithelial scores, suggesting FLASH acts as a repressor of the epithelial phenotype. Additionally, FLASH expression is inversely correlated with the epithelial score and subsets of mesenchymal markers are distinctly up-regulated in FLASH, NPAT, or SLBP-depleted cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang
Summary: Adipocytes are derived from pluripotent mesenchymal stem cells and histone modifications play a key role in their differentiation. Recent studies have shown that cancer stem cells can differentiate into adipocytes, reducing the malignancy of cancer cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat
Summary: Cancer heterogeneity and drug resistance are major obstacles to effective cancer treatment, and epigenetic modifications play a pivotal role in these processes. This review explores essential epigenetic modifications, including DNA methylation, histone modifications, and chromatin remodeling, and discusses their complex contributions to cancer biology. However, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to fully exploit the potential of epigenetic modifications.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo C. A. da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis
Summary: The TIS and IFN-gamma signatures are predictive biomarkers for identifying NSCLC patients who could potentially benefit from immune checkpoint inhibitor therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Giovanni Marchi, Anna Rajavuori, Mai T. N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Summary: The study shows that ctDNA can adequately represent high-grade serous ovarian carcinoma (HGSC), and the mutations observed at relapse suggest personalized therapy options.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yuncang Yuan, Jiawei Fan, Dandan Liang, Shijie Wang, Xu Luo, Yongjie Zhu, Nan Liu, Tingxiu Xiang, Xudong Zhao
Summary: This study demonstrates that csGRP78-directed CAR-T cells can selectively kill pancreatic cancer cells, and the combination with chemotherapy enhances cytotoxicity.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Niyati Piplani, Tanusri Roy, Neha Saxena, Shamik Sen
Summary: The glycocalyx, a protective barrier surrounding cells, has been found to play a role in cancer cell proliferation, survival, and metastasis. However, its function in maintaining DNA/nuclear integrity during migration through dense matrices has not been explored. This study shows that the bulkiness of the glycocalyx is inversely associated with nuclear stresses, and highlights its mechanical role in shielding migration-associated stresses.
TRANSLATIONAL ONCOLOGY
(2024)